Publications by authors named "Akifumi Kamiyama"
Patients with hematologic diseases have experienced coronavirus disease 2019 (COVID-19) with a prolonged, progressive course. Here, we present clinical, pathological, and virological analyses of three cases of prolonged COVID-19 among patients undergoing treatment for B-cell lymphoma. These patients had all been treated with anti-CD20 antibody and bendamustine.
View Article and Find Full Text PDFMonitoring viral dynamics can improve our understanding of pathogenicity and tissue tropism. Because the gene size of RNA viruses is typically small, NanoLuc is the primary choice for accommodation within viral genome. However, NanoLuc/Furimazine and also the conventional firefly luciferase/D-luciferin are known to exhibit relatively low tissue permeability and thus less sensitivity for visualization of deep tissue including lungs.
View Article and Find Full Text PDFMany methods have been developed to measure the neutralizing capacity of antibodies to SARS-CoV-2. However, these methods are low throughput and can be difficult to quickly modify in response to emerging variants. Therefore, an experimental system for rapid and easy measurement of the neutralizing capacity of antibodies against various variants is needed.
View Article and Find Full Text PDFArticle Synopsis
- The emergence of a new Variant of Interest, XBB.1.5, is linked to mutations from the pre-existing variant XBB.1, specifically an S486P spike mutation and a nonsense mutation in ORF8.
- Phylogenetic analysis indicates that XBB.1.5 maintains similar immune escape abilities compared to XBB.1, and structural studies reveal that the spike proteins of both variants are largely similar.
- Research involving hamsters shows that the ORF8 nonsense mutation in XBB.1.5 reduces MHC suppression and results in lower virulence in this variant compared to XBB.1.